Abstract

BackgroundPatients with prevalent or incident tuberculosis (TB) in antiretroviral treatment (ART) programmes in sub-Saharan Africa have high mortality risk. However, published data are contradictory as to whether TB is a risk factor for mortality that is independent of CD4 cell counts and other patient characteristics.Methods/FindingsThis observational ART cohort study was based in Cape Town, South Africa. Deaths from all causes were ascertained among patients receiving ART for up to 8 years. TB diagnoses and 4-monthly CD4 cell counts were recorded. Mortality rates were calculated and Poisson regression models were used to calculate incidence rate ratios (IRR) and identify risk factors for mortality. Of 1544 patients starting ART, 464 patients had prevalent TB at baseline and 424 developed incident TB during a median of 5.0 years follow-up. Most TB diagnoses (73.6%) were culture-confirmed. A total of 208 (13.5%) patients died during ART and mortality rates were 8.84 deaths/100 person-years during the first year of ART and decreased to 1.14 deaths/100 person-years after 5 years. In multivariate analyses adjusted for baseline and time-updated risk factors, both prevalent and incident TB were independent risk factors for mortality (IRR 1.7 [95% CI, 1.2–2.3] and 2.7 [95% CI, 1.9–3.8], respectively). Adjusted mortality risks were higher in the first 6 months of ART for those with prevalent TB at baseline (IRR 2.33; 95% CI, 1.5–3.5) and within the 6 months following diagnoses of incident TB (IRR 3.8; 95% CI, 2.6–5.7).ConclusionsPrevalent TB at baseline and incident TB during ART were strongly associated with increased mortality risk. This effect was time-dependent, suggesting that TB and mortality are likely to be causally related and that TB is not simply an epiphenomenon among highly immunocompromised patients. Strategies to rapidly diagnose, treat and prevent TB prior to and during ART urgently need to be implemented.

Highlights

  • HIV-associated tuberculosis (TB) remains a substantial challenge to international public health, accounting for an estimated 1.1 million new TB cases and 0.35 million deaths worldwide in 2010 [1]

  • Prevalent TB at baseline and incident TB during antiretroviral treatment (ART) were strongly associated with increased mortality risk

  • Prevalent TB at ART initiation was associated with a 1.7-fold increased mortality risk (IRR 1.67, 95% confidence intervals (CI) 1.23–2.25, p = 0.001)

Read more

Summary

Introduction

HIV-associated tuberculosis (TB) remains a substantial challenge to international public health, accounting for an estimated 1.1 million new TB cases and 0.35 million deaths worldwide in 2010 [1]. A staggering 82% of these cases and 71% of deaths were in sub-Saharan Africa [1]. This burden of disease represents a particular challenge to antiretroviral treatment (ART) programmes in the region as it is concentrated in patients accessing these services [2,3]. Patients with prevalent or incident tuberculosis (TB) in antiretroviral treatment (ART) programmes in subSaharan Africa have high mortality risk. Published data are contradictory as to whether TB is a risk factor for mortality that is independent of CD4 cell counts and other patient characteristics

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call